



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/632,342	08/01/2003	Jonathan C. Makielski	960296.98989	4060	
26734 7	590 06/30/2006		EXAM	EXAMINER	
	BRADY LLP	PAK, MICHAEL D			
FIRSTAR PLAZA, ONE SOUTH PINCKNEY STREET P.O. BOX 2113 SUITE 600			ART UNIT	PAPER NUMBER	
MADISON, W	VI 53701-2113		1646		
			DATE MAILED: 06/30/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)					
Office Action Commence		10/632,342	MAKIELSKI ET AI	L.				
	Office Action Summary	Examiner	Art Unit					
		Michael Pak	1646					
Period fo	The MAILING DATE of this communication app or Reply	pears on the cover shee	t with the correspondence ad	idress				
WHIC - Exter after - If NO - Failu Any r	CRTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING D. Insions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. In period for reply is specified above, the maximum statutory period or reply within the set or extended period for reply will, by statute the period by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMU 36(a). In no event, however, ma will apply and will expire SIX (6) , cause the application to become	JNICATION. By a reply be timely filed MONTHS from the mailing date of this come and the second sec	,				
Status								
1)	Responsive to communication(s) filed on							
•	<u> </u>	action is non-final.						
, —	·—							
- /	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
4)⊠)⊠ Claim(s) <u>1-50</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)[Claim(s) is/are allowed.							
6)□	Claim(s) is/are rejected.							
	Claim(s) is/are objected to.							
<u>,</u> 8)⊠	8) Claim(s) 1-50 are subject to restriction and/or election requirement.							
Applicati	on Papers							
9)□ ¹	The specification is objected to by the Examine	r.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority u	ınder 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
2) Notic 3) Inform	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	Paper	ew Summary (PTO-413) No(s)/Mail Date of Informal Patent Application (PTO	O-152)				

Application/Control Number: 10/632,342 Page 2

Art Unit: 1646

DETAILED ACTION

Election/Restrictions

Part I: Types of inventions.

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
- I. Claims 1-29, drawn to an isolated and purified polynucleotide, an expression vector, a host cell, a method for producing a polypeptide, classified in Class 435, subclass 69.1.
 - II. Claims 30-43, drawn to a polypeptide, classified in Class 530, subclass 350.
- III. Claim 44, drawn to a purified antibody, classified in Class 435, subclass 387.1.
- IV. Claim 45-46, drawn to a method for identifying an agent by sodium channel activity, classified in Class 435, subclass 7.2.
- V. Claim 47-48, drawn to a method for identifying an agent by expression of sodium channel mRNA, classified in Class 435, subclass 6.
- VI. Claim 48, drawn to a method for determining polypeptide with antibody, , classified in Class 436, subclass 518.
- VII. Claim 49, drawn to a method for determining mutation with disease, classified in Class 514, subclass 44.
- VIII. Claim 50, drawn to a method for determining risk to Long QT, classified in Class 435, subclass 172.1.

The inventions are distinct, each from the other because of the following reasons.

The products of any one of the inventions I-III, are distinct each from the other, because they are drawn to products having materially different structures and functions.

Inventions IV-VIII are distinct, each from the other, because they are drawn to processes having materially different process steps, which are practiced for materially different purposes.

The products of inventions I-III, and the process of invention IV-VIII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the alternative inventions I-III can be used in the alternative processs of Group IV-VIII.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their different classifications and recognized divergent subject matter, and the search required for any one of inventions I-VI is not required for any other invention I-VI, restriction for examination purposes as indicated is proper.

Part II: Sequences

Furthermore, restriction to one of the following inventions is required under 35 USC 121:

Application/Control Number: 10/632,342 Page 4

Art Unit: 1646

The inventions as they pertain to one sequence form of the mutant or SEQ ID NO:.

This is a further requirement for restriction into separately patentable groups.

Applicant must elect one sequence in order to be fully responsive. Because each receptor requires a unique search of the sequence in the literature databases and undue search burden would be imposed on the examiner if all of the sequences were examined on one patent application.

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Pak whose telephone number is 571-272-0879. The examiner can normally be reached on 8:30 - 2:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol can be reached on 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/632,342 Page 5

Art Unit: 1646

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Michael Pak

Primary Patent Examiner

Hicharl D. MAL

Art Unit 1646 19 June 2006